康泰医学 reported revenue of ¥0.23B for the period ended 2026-06-30, +3.8% year on year. Net income was ¥-0.05B, a -21.8% net margin on a 48.4% gross margin. The largest revenue line is 院线类产品 at 53% of the total. Free cash flow for the period was ¥0.00B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.23B | +3.8% |
| Gross profit | ¥0.11B | — |
| Operating income | ¥-0.05B | — |
| Net income | ¥-0.05B | -390.9% |
| Gross margin | 48.4% | Net margin -21.8% |
| Revenue Q/Q | +25.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 院线类产品 | ¥0.12B | 52.5% |
| 家用类产品 | ¥0.08B | 34.7% |
| 其他类产品 | ¥0.03B | 12.8% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.12B | 51.6% |
| R&D | ¥0.04B | 19.8% |
| SG&A | ¥0.07B | 29.2% |
| Tax & other | ¥-0.00B | -0.9% |
| Item | Amount |
|---|---|
| Total assets | ¥2.64B |
| Total liabilities | ¥0.96B |
| Shareholders' equity | ¥1.68B |
| Equity / assets | 63.8% |
| Operating cash flow | ¥0.01B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.00B |
| Cash conversion (OCF / net income) | -68% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
欧陆通 ・ 回盛生物 ・ 天阳科技 ・ 海晨股份 ・ 捷强装备 ・ 蒙泰高新 ・ 金春股份 ・ 维康药业 ・ 大叶股份 ・ 迦南智能 ・ 盛德鑫泰 ・ 万胜智能
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies